Kornimate/medical-research-clean huggingface dataset:
pelvic congestion syndrome and endometriosis

Conditions: Pelvic Congestive Syndrome; Endometriosis

Summary: the pelvic congestion syndrome (pcs) is a complex and multifactorial condition associated with inflammatory and hormonal etiophatogenesis similar to the endometriosis. furthermore, both pathologies share same clinical symptoms as chronic pelvic pain and dyspareunia. our hypothesis is that pcs prevalence is higher in patients with endometriosis than in those without clinical or ultrasound signs of endometriosis.

patients undergoing routine gynecological examinations are included in the study. patients are divided into 2 groups: * group a: with endometriosis * group b: without clinical or ultrasound signs of endometriosis this is an observational, monocentric, prospective, exploratory study. the aim is to assess pcs incidence, associated symptoms and ultrasound characteristics in patients with endometriosis and to compare those findings to those of patients who do not present clinical or ultrasound signs of endometriosis. the study also evaluates the correlation between: * type of pain symptoms (dysmenorrhea, chronic pelvic pain, ovulation pain, dyspareunia, dysuria, dyschezia) and pcs * pain severity (assessed according to vas scale from 0= no pain to 10= unbearable pain) and pcs * symptoms and ongoing medical treatments * history of pelvic surgery and pcs. ultrasound parameters of pelvic vascular insufficiency are: * ovarian vein diameter \<4mm * slow ovarian blood flow (\<3cm/sec) * retrograde blood flow * dilated arcuate veins communicating with pelvic varices * the presence of pelvic varices is evaluated qualitatively as normal, moderate and serious this evaluation includes the study of uterine and ovarian vessels, using different techniques: * standard 2d study: it allows to measure vessels diameter * vascular doppler study: it allows to evaluate flow direction and blood speed * 3d color study: it allows a three- dimensional reconstruction of vessels and a more accurate qualitative assessment of the congestion degree. * ultrasound images are evaluated independently by two operators.

Eligibility criteria:
inclusion criteria (group a): * obtaining informed consent * nulliparity * clinical or ultrasounds signs of endometriosis inclusion criteria (group b): * obtaining informed consent * nulliparity exclusion criteria: * menopause * actual or previous pregnancy
prevalence of spasticity in veterans living in a long-term care facility

Conditions: Spasticity

Summary: the purpose of the study is to conduct a feasibility survey of the prevalence of spasticity at a single long-term care facility for veterans and their spouses in murfreesboro, tennessee. these data will be used to strengthen a future grant application to the department of defense in response to their ongoing traumatic brain injury initiative.

the goal of this feasibility survey is to determine the prevalence of spasticity that interferes with care or function at the tennessee state veterans home (tsvh), which is a long-term care facility for veterans and their spouses in murfreesboro, tennessee. in order to accomplish this goal, each of the 140 residents will be examined by the principal investigator and a medical record review will be performed; also, each patient and their medical decision-maker (if applicable), direct caregiver, and treating physician will be surveyed in order to further elucidate the barriers to treatment in this population. all consenting residents of the tsvh will be examined, but the data will be separated prior to analysis based on whether the resident is a veteran or a veteran's relative.

Eligibility criteria:
inclusion criteria: * male and female subjects of any race, aged 18 and above. * reside at the tennessee state veterans home exclusion criteria: * subjects for whom it is felt that participation in the study would cause medical harm

Keywords: spasticity veterans prevalence
utilization of a 3d printed customized knee extender and at-home rehabilitation program on patient outcomes following acl surgery

Conditions: Anterior Cruciate Ligament Injuries; Anterior Cruciate Ligament Tear; Anterior Cruciate Ligament Rupture

Summary: the purpose of this study is to explore patient outcomes associated with, the use of a 3d printed knee extender device, in conjunction with an at-home rehabilitation program, for patients who are performing knee rehabilitation after anterior cruciate ligament (acl) surgery.


Eligibility criteria:
inclusion criteria: * diagnosed with a primary acl rupture. secondary knee pathology such as, but not limited to bone edema, strains, and meniscal pathology are acceptable as long as the primary injury and indication for surgery is the acl rupture. * able and willing to adhere to the study procedures * able to consent for self-, or able to assent for self with parental consent exclusion criteria: * pregnancy * non-english speaking

Keywords: 3d printing knee extender device
text -based depression screening among cancer survivors

Conditions: Cancer; Depression Secondary to Other Disease; Cancer Survivor

Summary: depression is common among cancer survivors, but current screening methods are not always effective. to help improve depression screening for cancer survivors, this study will conduct a pilot randomized controlled trial (rct) with 60 participants. the goal is to evaluate whether a text message-based approach to depression screening is feasible, acceptable, and potentially more effective than the current standard of care.

this pilot randomized controlled trial aims to evaluate the feasibility, acceptability, and preliminary efficacy of a text message-based depression screening approach for cancer survivors. a total of 60 adult cancer survivors will be enrolled and randomly assigned to either the text message intervention or the usual care depression screening. the intervention involves sending text messages one week before scheduled oncology appointments, inviting participants to complete a depression screening using the phq-2, followed by the phq-9 for those who screen positive. the study will assess the feasibility of implementing text message-based screenings, participant acceptability, and compare the efficacy of this method to traditional in-person depression screenings during clinical visits. the primary outcome is feasibility, measured by the proportion of participants completing the screening via text, while secondary outcomes will include acceptability (assessed through participant surveys) and preliminary efficacy (measured by screening completion rates and depression detection). eligible participants will be english-speaking cancer survivors aged 18 or older with an upcoming oncology appointment at the hollings cancer center or associated clinics. the study aims to improve current depression screening methods and address challenges such as logistical and system-level barriers in screening cancer survivors for depression.

Eligibility criteria:
inclusion criteria: * age \> 18 years * diagnosis of cancer * upcoming appointment in an hcc or hcn oncology clinic within 14 days * english proficiency * ownership of a cellphone with sms text capability.

Keywords: cancer survivorship depression screening text message screening mobile health
algrx 4975 in the treatment of tennis elbow

Conditions: Tennis Elbow

Summary: tennis elbow is a painful condition that results from repetitive arm movement with overuse of muscles, e.g. when playing tennis. a single injection of algrx 4975 has the potential to reduce pain for a period of weeks to months. this study will test the efficacy and safety of algrx 4975 in the treatment of patients with tennis elbow.

lateral epicondylitis (tennis elbow) is a painful condition that affects 4 to 7 adults per 1000 annually and tends to involve the subject's dominant side. it typically results from repetitive arm movement with over use of muscles leading to small tears in the tendons attaching muscles of the forearm to the epicondyles that may progress to tendonitis. pain on or around the lateral epicondyle may radiate down the subject's arm. gripping or extending the wrist often intensifies the pain. more than 40 possible treatments have been proposed, reflecting a lack of consensus about optimal management. non-steroidal anti-inflammatory drugs (nsaids) are commonly used to treat tennis elbow, but there are no trials to date that have compared them with other painkillers and one study found no clinically important benefit over placebo. use of corticosteroid injections provides mixed results in relief of pain and at times insufficient evidence to support their use. although complications associated with steroid injection are relatively uncommon, when a complication does occur, it can result in severe and disabling consequences for the subject. a small proportion of subjects fail to respond to only one injection of corticosteroid and some subjects who initially improved at four weeks had worse symptoms by six months. this study has been designed to evaluate the safety and efficacy of a single soft tissue injection of algrx 4975 at a dose of 100 µg in comparison to placebo in subjects with acute le.

Eligibility criteria:
inclusion criteria: * acute lateral epicondylitis (le) of less than 3 months duration (subjects with recurrent acute le may be included). * a screening and baseline severity of pain on resisted wrist dorsiflexion score of moderate or greater intensity. * lidocaine responsive. * a systolic and diastolic blood pressure not greater than 140 and 95 mm hg, respectively. exclusion criteria: * any clinically significant form of joint disease, elbow trauma or neuromuscular disorder at the elbow, other than acute le. * physiotherapy treatment within the preceding 2 weeks, prior to visit 1. * any systemic or local corticosteroids within the preceding 3 months, except nasal or inhaled steroids at less than or equal to 1000 mcg/day. * a medical condition other than le that requires the use of a pain medication. * a peripheral sensory or motor neuropathy involving the upper extremities.

Keywords: acute lateral epicondylitis tennis elbow capsaicin
survey on the treatment of anemia using recombinant human erythropoietin 2 (star-2)

Conditions: Anemia; Neoplasms

Summary: the main purpose of this study is to evaluate the safety and efficacy (% response) of epoetin alfa in the treatment of anemia in adults receiving chemotherapy for cancer.

anemia has been identified as a common complication and a widespread problem in the cancer population. anemia is a condition in which a patient has below normal levels of hemoglobin, the substance in red blood cells that carries oxygen to all parts of the body. people with severe anemia may experience fatigue and shortness of breath with activity. therefore, this condition can have a negative influence on a person's quality of life. epoetin alfa, used to treat anemia in cancer patients, is a genetically engineered protein that stimulates red blood cell production. this study investigates treatment of anemia using epoetin alfa during chemotherapy in adult patients with cancer. the study is intended to collect information on normal medical practice and routine anemia management performed at the participating centers. this is an observational, non-randomized, prospective, comparative, parallel-group survey performed in the netherlands. patients with various severities of disease may enter the survey as soon as their epoetin alfa treatment starts and will be followed until the end of their epoetin alfa treatment. patient data are collected in case report forms (crfs) until 4 weeks after the end of treatment with epoetin alfa. at the end of treatment completed crfs will be collected. the assessment of effectiveness/response will be based on the following: cancer type and status, chemotherapy and other anti-cancer treatment, hemoglobin levels, use of blood transfusions, and serum iron levels and iron supplementation. safety evaluations include the incidence of serious and non-serious adverse events. because the study is observational, dosage, administration and duration of treatment is at discretion of treating physician.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of solid tumors, multiple myeloma (kahlers' disease), non-hodgkin lymphoma or hodgkins' disease * patients must already be receiving chemotherapy or start their first cycle within a week of enrollment * patients must receive epoetin alfa treatment (expected treatment duration is at least 4 weeks) exclusion criteria: * patients who cannot read the dutch language and/or do not understand the dutch informed consent form and patients participating in either of our observational studies, evaluate or compare

Keywords: anemia neoplasms antineoplastic agents chemotherapy efficacy epoetin alfa
comparison of changes in the quality of life of patients operated on breast cancer at the drôme ardèche breast institute according to access to supportive oncological care (idsein)

Conditions: Breast Cancer Female

Summary: the aim of this study is to explore the quality of life of cancer patients, in particular women operated on breast cancer, throughout their care journey, taking into account their access to supportive oncological care within and outside the establishment care.


Eligibility criteria:
inclusion criteria: * woman with histologically confirmed invasive breast cancer for whom surgery is scheduled * age\> 18 years old * performance status ecog \<2 * patient speaking and understanding french and able to complete questionnaires * patient affiliated or beneficiary of a social security scheme * patient having read the information note and not objecting to the use of the data collected exclusion criteria: * male * patient treated with neoadjuvant chemotherapy * patient participating in a therapeutic trial * patient with metastatic breast cancer * patient with bilateral breast cancer * history of cancer of less than 5 years * active infection or other serious underlying condition that may prevent the patient from receiving treatment * history or progressive psychiatric illness * person deprived of liberty or under guardianship * inability to undergo medical monitoring for geographical, social or psychological reasons indication of emergency amputation * protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision * pregnant, breastfeeding or parturient woman * patient hospitalized without consent
genetic feature of congenital hearing loss in chinese population

Conditions: Congenital Hearing Loss; Congenital Deafness

Summary: congenital hearing loss, as well as hearing loss present at birth, is one of the most common chronic conditions in children, with a prevalence of permanent bilateral hearing loss of 2.83 per 1000 children of primary school age, which is mainly caused by genetic factors. the goal of this observational study is to learn about novel causative genes in infants with hearing loss in the chinese population. the main problem it aims to deal with are: * to present the genetic characteristics of the infant with hearing loss in the chinese population * to build up a prognostic model base on diverse data. participants will be asked to receive audiological tests and collection of the peripheral blood sample.


Eligibility criteria:
inclusion criteria: * age up to 6 months * fail in the neonatal hearing screening programs, including oto-acoustic emissions and automated auditory brain stem response * promise to complete the tests required at baseline and follow-ups by the legal representative * informed consent by the legal representative exclusion criteria: * congenital infections related to acquired or congenital hearing loss, including rubella virus, cytomegalovirus, herpes simplex virus, rubella virus, toxoplasma gondii and treponema pallidum infections * other explicit otologic conditions which could induce hearing loss, including cerumen, otitis media, congenital middle ear abnormalities, microtia and external ear abnormalities * a drug with ototoxicity usage during pregnancy * other severe congenital anomalies
"curamed" and "curamin" in osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: this randomized, placebo-controlled study evaluates the effects of curamed ® (bcm-95 ®) and curamin ® in the treatment of osteoarthritis. one group will receive curamed, one group will receive curamin and one group will receive placebo.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of degenerative hypertrophic osteoarthritis of the knee (m17, according to international classification of diseases (icd-10) of bone joints, verified by radiography (grade 1-3 by kellgren-lawrence radiographic grades). exclusion criteria: * subjects with inflammatory and any secondary arthritis * moderate and severe synovitis (grades 2 and 3) * tear of meniscus * chronic diseases of the kidneys, liver, gastrointestinal, cardiovascular, endocrine and nervous systems * allergic anamnesis and drug intolerance * pregnant or nursing * history of substance abuse * subjects taking non-steroidal anti-inflammatory drugs and analgesics within 2 weeks prior to the study * subjects taking glucosamine sulfate, chondroitin sulfate, intra-articular hyaluronate, systemic or intra-articular glucocorticoids within three months prior to the study
safety, tolerability and pharmacokinetics of sar113945 in japanese patients with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: primary objective: to assess the safety and tolerability of sar113945 in japanese patients with knee osteoarthritis after ascending single intra-articular doses secondary objective: to assess the pharmacokinetics of sar113945 in japanese patients with knee osteoarthritis after ascending single intra-articular doses

following the single dose of study medication, the study period for each patient will be 168 days.

Eligibility criteria:
inclusion criteria: * japanese male or female patients, aged 40 years or older, with knee osteoarthritis * diagnosis of primary knee osteoarthritis, based upon the following: * x-ray or magnetic response imaging (mri) evidence within the last 6 months for joint space narrowing and osteophyte formation * patients will be kellegen and lawrence classification ii or iii, and total western ontario mcmaster (womac) score below or equal to 72 * patients fulfilling the american college of rheumatology clinical and radiographic criteria for osteoarthritis exclusion criteria: * women of child bearing potential * secondary osteoarthritis: e.g., autoimmune disease, joint dysplasia, aseptic osteonecrosis, acromegaly, paget's disease, ehlers-danlos syndrome, gaucher's disease, stickler's syndrome, joint infection, hemophilia, hemochromatosis, calcium pyrophosphate disposition disease, or neuropathic arthropathy * presence of local skin abnormality at the affected knee joint * any patient who received intra-articular injection within 3 months prior to administration the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
apneic oxygenation for morbid obese parturient in cs

Conditions: Morbid Obesity

Summary: the aim of this study is to compare the effect of apneic preoxygenation to conventional preoxygenation on the oxygen desaturation in morbid obese parturient performing elective caesarean section under general anesthesia.

anesthetic management of the obese parturient is challenging. both pregnancy and obesity are risk factors for a difficult airway and anesthesia-related maternal mortality. there is increased risk of difficult intubation associated with an increased difficultly in mask ventilation and increased risk of accelerated desaturation during apnea. the use of apneic oxygenation for the optimization of peri-intubation conditions is a promising means of preventing hypoxemia. despite the recommendation of the use of nasal prongs to insufflate oxygen at flows of 5 l/min to 15 l/min during the apneic period randomized controlled trial is still not available in the morbidly obese parturient.

Eligibility criteria:
inclusion criteria: 1. morbid obesity parturient defined as a body mass index (bmi) above 40 kg/m2. 2. asa physical status i-ii 3. age above 18 years. 4. scheduled for elective caesarean section under general anesthesia. exclusion criteria: 1. parturient of asa physical status iii or above. 2. suspected or known difficult airway (mallampati class \> 2, reduced neck movement, reduced mouth opening, or cormack-lehane grade 4 recorded during a previous intubation procedure). 3. any contraindication for nasal prong use, for example, tumours, fractures or trauma. 4. spo2 ≤ 97% prior to preoxygenation.
a ketogenic diet as a complementary treatment on patients with high-grade gliomas and brain metastases

Conditions: Brain; Cancer

Summary: the survival interval of patients with gliomas ranges between 12 to 15 months. recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic effect. ketosis can be an effective therapy to extend the survival of patients with gliomas.

gliomas are invasive and aggressive tumors, which derive from glial or stem cells, and after neoplastic transformation, acquire glial cell characteristics. treatment of high-grade gliomas includes measures to relieve symptoms and eliminate or control the tumor. surgery, radiation, and chemotherapy are the most common options. recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic effect. ckd is a restrictive therapeutic diet consisting of a 4:1 ratio of fat-to-cho and protein. fat provides up to 90% of the caloric intake, while overall cho intake is less than 50 g/day. ckd reducing blood glucose levels and increasing ketone body levels stimulates biochemical changes to achieve systemic ketosis. though, evidence for ckd in clinical practice is still limited. this study focuses on the classic ketogenic diet (ckd), adjusted for each patient's energy needs by dieticians to achieve ketosis. the primary outcome is to assess the efficacy of ckd to extend the survival of patients with high-grade gliomas and brain metastases. historical controls will be used to compare the outcome measurements.

Eligibility criteria:
inclusion criteria: * age 18-80 * karnofsky performance score of 50 or more. * newly diagnosed, histologically confirmed glioblastoma grade 4, or secondary metastases or progression after surgical resection, radiation and chemotherapy. * normal function of liver and kidneys * ability to sign informed consent form exclusion criteria: * diabetes mellitus * life expectancy \>3 months * inability to adhere to diet * inability to give informed consent form * cholecystectomy last 1 year (before the study entry) * diagnosis of genetic disorder of fat metabolism

Keywords: ketogenic diet gliomas metastases